期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma:New hopes on the horizon
1
作者 Leonardo S Lino-Silva Sabrina B Martínez-Villavicencio Luisa Fernanda Rivera-Moncada 《World Journal of Clinical Oncology》 2024年第5期587-590,共4页
In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotr... In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotrexate(HD-MTX)as a therapeutic intervention for primary central nervous system lymphoma(PCNSL).The study involves a retrospective analysis of 19 PCNSL patients,highlighting clinicopathological characteristics,treatment outcomes,and genomic biomarkers.The results indicate the combination’s good tolerance and strong antitumor activity,with an 84.2%overall response rate.The authors emphasize the potential of zanubrutinib to modulate key genomic features of PCNSL,particularly mutations in myeloid differentiation primary response 88 and cluster of differentiation 79B.Furthermore,the study investigates the role of circulating tumor DNA in cerebrospinal fluid for disease surveillance and treatment response monitoring.In essence,the study provides valuable insights into the potential of combining zanubrutinib with HD-MTX as a frontline therapeutic regimen for PCNSL.The findings underscore the importance of exploring alternative treatment modalities and monitoring genomic and liquid biopsy markers to optimize patient outcomes.While the findings suggest promise,the study’s limitations should be considered,and further research is needed to establish the clinical relevance of this therapeutic approach for PCNSL. 展开更多
关键词 Primary central nervous system lymphoma Zanubrutinib bruton’s tyrosine kinase PROGNOsIs Myeloid differentiation primary response 88 gene Cluster of differentiation 79B gene
下载PDF
原发性低丙种球蛋白血症Bruton’S酪氨酸激酶表达研究(摘要)
2
作者 王晓川 《复旦学报(医学版)》 CAS CSCD 北大核心 2004年第4期339-339,共1页
关键词 原发性低丙种球蛋白血症 bruton’s酪氨酸激酶 表达 单核细胞
下载PDF
Novel deletion mutation in Bruton’s tyrosine kinase results in X-linked agammaglobulinemia:A case report
3
作者 Xiao-Mei Hu Ke Yuan +5 位作者 Hong Chen Chun Chen Yan-Lan Fang Jian-Fang Zhu Li Liang Chun-Lin Wang 《World Journal of Clinical Cases》 SCIE 2020年第17期3859-3866,共8页
BACKGROUND X-linked agammaglobulinemia is a primary immunodeficiency disease caused by gene mutations of Bruton’s tyrosine kinase(BTK).We found a new mutation point and summarized the correlation analysis and perform... BACKGROUND X-linked agammaglobulinemia is a primary immunodeficiency disease caused by gene mutations of Bruton’s tyrosine kinase(BTK).We found a new mutation point and summarized the correlation analysis and performed a literature review.CASE SUMMARY The proband was a 5-year-old boy.He was admitted to our hospital due to a recurrent cough and a fever that had persisted for a month.He had a history of multiple respiratory infections and sinusitis.There was no immunodeficiency or recurrent infection history among his family members.Agammaglobulinemia was characterized as follows:Immunoglobulin(Ig)A,90.0 mg/dL(90-450 mg/dL);IgG,20.0 mg/dL(800-1800 mg/dL);and IgM,18.0 mg/dL(60-280 mg/dL).Notably,the assessment of IgG subtypes revealed the following very low levels:Subtype 1,0.26 g/L(3.62-12.28 g/L);subtype 2,0.10 g/L(0.57-2.9 g/L);subtype 3,0.009 g/L(0.129-0.789 g/L);and subtype 4,0.003 g/L(0.013-1.446 g/L).Cellular immunological test results were as follows:CD3,74.6%(50%-84.0%);CD4,47.3%(27.0%-51.0%);and CD8,24.9%(15.0%-44.0%).A de novo hemizygous deletion in BTK was detected:c.902_c.904delAAG/p.E301del.Transcript levels of the mutant BTK were similar to those of the wild-type gene,though overexpression resulted in markedly reduced levels of mutant BTK(9.49%±1.58%),relative to the wildtype BTK(75.8%±2.98%,P<0.01).CONCLUSION This case of X-linked agammaglobulinemia was attributed to a de novo hemizygous deletion mutation in BTK(c.902_c.904delAAG/p.E301del).The mutation resulted in markedly reduced BTK protein stability in vitro. 展开更多
关键词 AGAMMAGLOBULINEMIA bruton’s tyrosine kinase MUTATION IMMUNODEFICIENCY Case report
下载PDF
Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments
4
作者 Michele Barone 《World Journal of Gastroenterology》 SCIE CAS 2024年第25期3147-3151,共5页
In this editorial,we discussed the apparent discrepancy between the findings described by Colapietro et al,in their case report and data found in the literature.Colapietro et al reported a case of hepatitis B virus(HB... In this editorial,we discussed the apparent discrepancy between the findings described by Colapietro et al,in their case report and data found in the literature.Colapietro et al reported a case of hepatitis B virus(HBV)-related hepatic decompensation in a patient with chronic myeloid leukemia and a previously resolved HBV infection who was receiving Bruton’s tyrosine kinase(BTK)inhibitor therapy.First of all,we recapitulated the main aspects of the immune system involved in the response to HBV infection in order to underline the role of the innate and adaptive response,focusing our attention on the protective role of anti-HBs.We then carefully analyzed literature data on the risk of HBV reactivation(HBVr)in patients with previous HBV infection who were treated with either tyrosine kinase inhibitors or BTK inhibitors for their hematologic malignancies.Based on literature data,we suggested that several factors may contribute to the different risks of HBVr:The type of hematologic malignancy;the type of therapy(BTK inhibitors,especially second-generation,seem to be at a higher risk of HBVr than those with tyrosine kinase inhibitors);previous exposure to an anti-CD20 as first-line therapy;and ethnicity and HBV genotype.Therefore,the warning regarding HBVr in the specific setting of patients with hematologic malignancies requires further investigation. 展开更多
关键词 Hematological malignancy HEPATITIs Hepatitis B virus-DNA bruton’s tyrosine kinase Previously resolved hepatitis B virus infection
下载PDF
Ibrutinib and atrial fibrillation:An in-depth review of clinical implications and management strategies
5
作者 Moiud Mohyeldin Shitij Shrivastava Sai Vishnu Vardhan Allu 《World Journal of Cardiology》 2024年第5期269-273,共5页
Ibrutinib,a targeted therapy for B-cell malignancies,has shown remarkable efficacy in treating various hematologic cancers.However,its clinical use has raised concerns regarding cardiovascular complications,notably at... Ibrutinib,a targeted therapy for B-cell malignancies,has shown remarkable efficacy in treating various hematologic cancers.However,its clinical use has raised concerns regarding cardiovascular complications,notably atrial fibrillation(AF).This comprehensive review critically evaluates the association between ibrutinib and AF by examining incidence,risk factors,mechanistic links,and management strategies.Through an extensive analysis of original research articles,this review elucidates the complex interplay between ibrutinib’s therapeutic benefits and cardiovascular risks.Moreover,it highlights the need for personalized treatment approaches,vigilant monitoring,and interdisciplinary collaboration to optimize patient outcomes and safety in the context of ibrutinib therapy.The review provides a valuable resource for healthcare professionals aiming to navigate the intricacies of ibrutinib’s therapeutic landscape while prioritizing patient well-being. 展开更多
关键词 Ibrutinib bruton’s tyrosine kinase inhibitor Atrial fibrillation Cardiovascular risk Management strategies
下载PDF
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era 被引量:10
6
作者 Joyce Wing Yan Mak Alvin Wing Hin Law +3 位作者 Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law 《World Journal of Gastroenterology》 SCIE CAS 2023年第33期4942-4961,共20页
Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing... Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation.Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver.The expression of these silent genomes is controlled by the immune system.Suppression or ablation of immune cells,most importantly B cells,may lead to reactivation of seemingly resolved HBV infection.Thus,all patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBsAg)and antibody to hepatitis B core antigen.Patients found to be positive for HBsAg should be given prophylactic antiviral therapy.For patients with resolved HBV infection,there are two approaches.The first is pre-emptive therapy guided by serial HBV DNA monitoring,and treatment with antiviral therapy as soon as HBV DNA becomes detectable.The second approach is prophy-lactic antiviral therapy,particularly for patients receiving high-risk therapy,especially anti-CD20 monoclonal antibody or hematopoietic stem cell transplantation.Entecavir and tenofovir are the preferred antiviral choices.Many new effective therapies for hematological malignancies have been introduced in the past decade,for example,chimeric antigen receptor(CAR)-T cell therapy,novel monoclonal antibodies,bispecific antibody drug conjugates,and small molecule inhibitors,which may be associated with HBV reactivation.Although there is limited evidence to guide the optimal preventive measures,we recommend antivi-ral prophylaxis in HBsAg-positive patients receiving novel treatments,including Bruton’s tyrosine kinase inhibitors,B-cell lymphoma 2 inhibitors,and CAR-T cell therapy.Further studies are needed to determine the risk of HBV reactivation with these agents and the best prophylactic strategy. 展开更多
关键词 Hepatitis B Hematologic neoplasms Chimeric antigen receptor-T cell therapy Monoclonal antibodies bruton’s tyrosine kinase inhibitors Antiviral agents
下载PDF
10例X连锁无丙种球蛋白血症的临床分析和基因诊断 被引量:7
7
作者 张志勇 赵晓东 +5 位作者 王墨 蒋利萍 崔玉霞 赵耀 安云飞 杨锡强 《免疫学杂志》 CAS CSCD 北大核心 2009年第6期709-712,共4页
目的通过对X连锁无丙种球蛋白血症(XLA)患儿Bruton’s酪氨酸激酶(BTK)基因变异和临床特征的分析,提高临床医师对XLA的认识。方法收集2008年2月至2008年12月在我院住院的10例XLA患儿外周静脉血,采用RT-PCR方法扩增BTK cDNA,PCR产物直接... 目的通过对X连锁无丙种球蛋白血症(XLA)患儿Bruton’s酪氨酸激酶(BTK)基因变异和临床特征的分析,提高临床医师对XLA的认识。方法收集2008年2月至2008年12月在我院住院的10例XLA患儿外周静脉血,采用RT-PCR方法扩增BTK cDNA,PCR产物直接双向测序。突变结果经DNA相应外显子部位扩增、测序进一步证实。结果10例XLA患儿中7例患儿发现有BTK基因突变。6例位于编码区,1例位于内含子区。突变类型包括错义突变3例,无义突变1例,缺失2例和内含子剪接位点突变1例。其中5例(F583L,135Nfs177X,R123X,C502Y,IVS9+2T>C)为首次报道的新型突变。进行基因分析的6例XLA患儿母亲均为携带者。结论BTK基因分析有助于XLA患儿的进一步明确诊断,而且有利于发现携带者和进行遗传咨询。 展开更多
关键词 X连锁无丙种球蛋白血症 bruton’s酪氨酸激酶 突变分析 分子诊断
下载PDF
原发性低丙种球蛋白血症Bruton′s酪氨酸激酶表达研究 被引量:3
8
作者 王晓川 俞晔珩 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2004年第2期120-123,共4页
目的 研究临床诊断为原发性低丙种球蛋白血症Bruton′s酪氨酸激酶 (BTK)表达及意义。方法 使用抗BTK单克隆抗体通过流式细胞仪技术分析细胞内BTK表达。经临床和常规实验室检查诊断为原发性低丙种球蛋白血症的 8例来自不同家系的患者... 目的 研究临床诊断为原发性低丙种球蛋白血症Bruton′s酪氨酸激酶 (BTK)表达及意义。方法 使用抗BTK单克隆抗体通过流式细胞仪技术分析细胞内BTK表达。经临床和常规实验室检查诊断为原发性低丙种球蛋白血症的 8例来自不同家系的患者和其中 5例患者的母亲。结果 正常对照者单核细胞BTK表达均大于 95 %。 8例受检患者中 7例单核细胞中BTK表达明显降低 ,基因分析存在BTK突变。 1例BTK表达正常 ,基因分析BTK正常。检测的 5例患者母亲中 3例单核细胞BTK表达降低 ,BTK基因分析也表现为嵌合型。 2例BTK表达正常 ,BTK基因正常。结论 通过流式细胞仪检测单核细胞内BTK表达可作为诊断X 连锁无丙种球蛋白血症 (XLA)手段之一 ,并可能用于甄别XLA携带者。 展开更多
关键词 原发性低丙种球蛋白血症 bruton’s酪氨酸激酶 单克隆抗体 流式细胞仪 X-连锁无丙种球蛋白血症
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部